Mechanism of hepatobiliary toxicity of the LPA1 antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: Contrasts with BMS-986234 and BMS-986278-Reference-Cited by-同舟云学术

Mechanism of hepatobiliary toxicity of the LPA1 antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: Contrasts with BMS-986234 and BMS-986278

Published:2022-03 Issue: Volume:438 Page:115885
ISSN:0041-008X
Container-title:Toxicology and Applied Pharmacology
language:en
Short-container-title:Toxicology and Applied Pharmacology

Author:

Gill Michael W.,Murphy Brian J.,Cheng Peter T.W.,Sivaraman Lakshmi,Davis Myrtle,Lehman-McKeeman Lois

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Pharmacology,Toxicology

Reference49 articles.

1. Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump;Aleo;Hepatology,2014

2. Evaluating the role of multidrug resistance protein 3 (MDR3) inhibition in predicting drug-induced liver injury using 125 pharmaceuticals;Aleo;Chem. Res. Toxicol.,2017

3. Acyl glucuronide reactivity in perspective: biological consequences;Bailey;Chem. Biol. Interact.,2003

4. Modeling drug- and chemical-induced hepatotoxicity with systems biology approaches;Bhattacharya;Front. Physiol.,2012

5. Studies on the mechanisms of bile acid initiated hepatic inflammation in cholestatic liver injury;Cai;Inflamm. Cell Signal.,2017

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oleanolic acid induces hepatic injury by disrupting hepatocyte tight junction and dysregulation of farnesoid X receptor‐mediated bile acid efflux transporters;Journal of Applied Toxicology;2024-07-18

2. Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis;European Respiratory Review;2024-04-30

3. Downregulation of HMGCS2 mediated AECIIs lipid metabolic alteration promotes pulmonary fibrosis by activating fibroblasts;Respiratory Research;2024-04-24

4. Molecular Pathways Governing the Termination of Liver Regeneration;Pharmacological Reviews;2024-03-04

5. Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular Scaffold;Journal of Medicinal Chemistry;2024-02-13